Managers

On the Bleeding Edge: Zucked by Roger McNamee

Bill Maris' Section 32 raises $199.4 mln for second venture fund

Bill Maris' Section 32 has raised $199.4 million for a second venture-capital fund, according to a filing with the SEC.

Gracell inks $85 mln Series B

China-based Gracell, a cellular gene therapy company, has secured $85 million in Series B funding. Temasek led the round with participation from Lilly Asia Ventures, Kington Capital, King Star Capital and Chengdu Miaoji.

Scaleworks raises $80 mln for sophomore fund

Scaleworks has closed its second flagship fund at $80 million. Based in San Antonio, Scaleworks is a B2B SaaS-focused venture firm.

Fund performance: Nevada PERS, 2012 vintage

Has SXSW jumped the shark or is it alluring? Tell me if you'll be there.

Jerusalem Venture Partners raises $220 mln eighth venture-capital fund

Jerusalem Venture Partners has raised a $220 million eighth venture-capital fund, according to a tweet.

Clareto lands Series A funding

Clareto, a health data network, has raised an undisclosed amount of Series A funding. Health Catalyst Capital Management LLC led the round.

Geneos Therapeutics snags $10.5 mln Series A

Pennsylvania-based Geneos Therapeutics, a developer of cancer therapies, has raised $10.5 million in Series A funding. Santé Ventures led the round with participation from Inovio.

MPM Capital collects $400 mln for bioventure fund

MPM Capital has raised $400 million for its seventh venture fund BioVentures 2018. MPM focuses on companies that develop therapies "to treat severe unmet medical needs."